FED CUTS Fed slashes interest rates by 25 basis points in 2nd consecutive cut Stuttgart - Delayed Quote ? EUR Ardelyx Inc (41X.SG) Follow Compare 5.80 -0.17 (-2.78%) As of 7:26 PM GMT+1. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Michael Raab, President and CEO, Justin Renz, Chief Financial and Operations Officer and Eric Foster, Chief Commercial Officer, will participate in a fireside chat at the 2024 Jefferies London Healthcare Conference on Tuesday, No GlobeNewswire ? 2 days ago ARDX Ardelyx Third Quarter 2024 Earnings: US$0.003 loss per share (vs US$0.03 profit in 3Q 2023) Ardelyx ( NASDAQ:ARDX ) Third Quarter 2024 Results Key Financial Results Revenue: US$98.2m (up 74% from 3Q 2023). Net... Simply Wall St. ? 5 days ago ARDX Q3 2024 Ardelyx Inc Earnings Call Q3 2024 Ardelyx Inc Earnings Call Thomson Reuters StreetEvents ? 6 days ago ARDX Ardelyx Inc (ARDX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Growth Amidst ... Ardelyx Inc (ARDX) reports significant revenue growth and strategic advancements, while navigating Medicare uncertainties and increased expenses. GuruFocus.com ? 6 days ago ARDX Compared to Estimates, Ardelyx (ARDX) Q3 Earnings: A Look at Key Metrics The headline numbers for Ardelyx (ARDX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. Zacks ? 6 days ago ARDX Ardelyx (ARDX) Reports Break-Even Earnings for Q3 Ardelyx (ARDX) delivered earnings and revenue surprises of 100% and 13.89%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? 6 days ago ARDX Ardelyx: Q3 Earnings Snapshot ARDX) on Thursday reported a third-quarter loss of $809,000, after reporting a profit in the same period a year earlier. On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of less than 1 cent. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of 5 cents per share. Associated Press Finance ? 7 days ago ARDX Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update IBSRELA generates $40.6 million in net product sales revenue; Company expects full year 2024 IBSRELA net sales revenue to be between $145 and $150 million XPHOZAH generates $51.5 million in net product sales revenue Company ends Q3 with approximately $190 million in cash, cash equivalents and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, GlobeNewswire ? 7 days ago ARDX Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology’s (ACG) Annual Meeting Ninety percent of survey participants reported “some” or “significant” negative impact of IBS-C on their life Survey results presented in two poster presentations WALTHAM, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that results from the IBS in America 2024 supplemental survey, in partn GlobeNewswire ? 10 days ago ARDX Zoetis (ZTS) Reports Next Week: Wall Street Expects Earnings Growth Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Zacks ? 10 days ago ZTS ARDX Ardelyx Shares Additional Data Supporting First-In-Class XPHOZAH? (tenapanor) at the American Society of Nephrology’s Kidney Week WALTHAM, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that data supporting additional positive clinical observations of XPHOZAH? (tenapanor) was presented in a series of poster presentations at the American Society of Nephrology’s (ASN) Kidney Week, currently taking place in San Diego. A GlobeNewswire ? 14 days ago ARDX Earnings Preview: Ardelyx (ARDX) Q3 Earnings Expected to Decline Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Zacks ? 14 days ago ARDX UTHR Ardelyx Announces Launch of Gut Matters: Discoveries and Innovations, a New Podcast for the IBS-C Patient Community WALTHAM, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the launch of Gut Matters: Discoveries and Innovations, a new podcast for the irritable bowel syndrome with constipation (IBS-C) patient community. The podcast is hosted by Ardelyx’s director, patient advocacy, Johannah Ruddy, M.Ed. a GlobeNewswire ? 16 days ago ARDX Ardelyx Announces the Derek Forfang Patient Advocate Award to Recognize Advocates for the Chronic Kidney Disease Community Deadline to submit nominations is January 31, 2025WALTHAM, Mass., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the launch of the Derek Forfang Patient Advocate Award to recognize passionate supporters of patients living with chronic kidney disease (CKD) who champion the need for innovation and GlobeNewswire ? 17 days ago ARDX Here's Why Ardelyx (ARDX) Could be Great Choice for a Bottom Fisher After losing some value lately, a hammer chart pattern has been formed for Ardelyx (ARDX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term. Zacks ? 20 days ago ARDX Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024 Conference call scheduled for 4:30 p.m. Eastern TimeWALTHAM, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, October 31, 2024, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the third quarter of 2024. To GlobeNewswire ? 21 days ago ARDX Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH? (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology’s Kidney Week WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that additional data supporting XPHOZAH? (tenapanor) will be presented at the American Society of Nephrology’s (ASN) Kidney Week, to be held October 24-27, 2024, in San Diego. XPHOZAH, the first and only phosphate absorption inhibitor GlobeNewswire ? 23 days ago ARDX Ardelyx Inc (ARDX) Q2 2024 Earnings Call Highlights: Revenue Surge and Strategic Challenges Ardelyx Inc (ARDX) reports significant revenue growth amid strategic hurdles, with a focus on expanding market access for XPHOZAH. GuruFocus.com ? 29 days ago ARDX Even though Ardelyx (NASDAQ:ARDX) has lost US$210m market cap in last 7 days, shareholders are still up 352% over 3 years Ardelyx, Inc. ( NASDAQ:ARDX ) shareholders might be concerned after seeing the share price drop 13% in the last week... Simply Wall St. ? 29 days ago ARDX Ardelyx Announces Publication of a Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology WALTHAM, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the recent publication of a review article, titled “Review of the Patient Burden and Therapeutic Landscape of Irritable Bowel Syndrome With Constipation in the United States” in Clinical and Experimental Gastroenterology, an internati GlobeNewswire ? 29 days ago ARDX Performance Overview Trailing total returns as of 11/7/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return 41X.SG S&P 500 YTD +1.47% +25.39% 1-Year +56.02% +36.99% 3-Year +474.65% +27.32%
